Key facts
- This page summarizes Emma Reeve's Form 4 filing for Editas Medicine, Inc. (EDIT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2024, 16:30.
Emma Reeve - 30 May 2024 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)
- Reporting relationship
- Director
- Issuer ticker
- EDIT
- Reported as of
- 30 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2024, 16:30:27 UTC
- Prior SEC filing
- 16 Feb 2024
- Next SEC filing
- 14 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Emma Reeve
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Emma Reeve filed Form 4 for Editas Medicine, Inc. (EDIT) on 03 Jun 2024.
Change
- Previous filing in this sequence was filed on 16 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EDIT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 30 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $5.17
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025